Functional domains of APOBEC3G required for antiviral activity
- PMID: 15156567
- DOI: 10.1002/jcb.20082
Functional domains of APOBEC3G required for antiviral activity
Abstract
The viral protein, Vif, is essential for the production of infectious progeny virions in natural target cells of human immunodeficiency virus type 1 (HIV-1). Several recent reports indicate that Vif acts by antagonizing the activity of an endogenous human antiviral protein, APOBEC3G. To investigate this route to restrict HIV-1 infection, we employed mutagenesis to assess APOBEC3G function during HIV-1 infection including interaction with Vif, localization, and activity in virions. We found that APOBEC3G binds Vif in infected cells and the C'-terminal region is required for this interaction. APOBEC3G was only incorporated into virions in the absence of Vif and deletion of either the N'-terminal or C'-terminal regions of APOBEC3G abrogated virion localization. Assaying endogenous reverse transcription we found that APOBEC3G and its C'-terminal deletion mutant inhibited full-length cDNA synthesis, possibly through binding to viral RNA, a function revealed through gel-shift assays. Taken together, our studies suggest that APOBEC3G inhibits HIV-1 infection through interference with reverse transcription and that Vif counteracts APOBEC3G by impeding its entry into virions.
Copyright 2004 Wiley-Liss, Inc.
Similar articles
-
HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability.Mol Cell. 2003 Sep;12(3):591-601. doi: 10.1016/s1097-2765(03)00353-8. Mol Cell. 2003. PMID: 14527406
-
Influence of primate lentiviral Vif and proteasome inhibitors on human immunodeficiency virus type 1 virion packaging of APOBEC3G.J Virol. 2004 Feb;78(4):2072-81. doi: 10.1128/jvi.78.4.2072-2081.2004. J Virol. 2004. PMID: 14747572 Free PMC article.
-
Specific packaging of APOBEC3G into HIV-1 virions is mediated by the nucleocapsid domain of the gag polyprotein precursor.Virology. 2004 Oct 25;328(2):163-8. doi: 10.1016/j.virol.2004.08.006. Virology. 2004. PMID: 15464836
-
New insights into the role of Vif in HIV-1 replication.AIDS Rev. 2004 Jan-Mar;6(1):34-9. AIDS Rev. 2004. PMID: 15168739 Review.
-
Recent insights into HIV-1 Vif.Curr Opin Immunol. 2004 Aug;16(4):477-82. doi: 10.1016/j.coi.2004.05.006. Curr Opin Immunol. 2004. PMID: 15245742 Review.
Cited by
-
Monomeric APOBEC3G is catalytically active and has antiviral activity.J Virol. 2006 May;80(10):4673-82. doi: 10.1128/JVI.80.10.4673-4682.2006. J Virol. 2006. PMID: 16641260 Free PMC article.
-
Towards Inhibition of Vif-APOBEC3G Interaction: Which Protein to Target?Adv Virol. 2010;2010:649315. doi: 10.1155/2010/649315. Epub 2010 Sep 21. Adv Virol. 2010. PMID: 22347227 Free PMC article.
-
Multiple ways of targeting APOBEC3-virion infectivity factor interactions for anti-HIV-1 drug development.Trends Pharmacol Sci. 2009 Dec;30(12):638-46. doi: 10.1016/j.tips.2009.09.006. Trends Pharmacol Sci. 2009. PMID: 19837465 Free PMC article. Review.
-
Human immunodeficiency virus type 1 Vif inhibits packaging and antiviral activity of a degradation-resistant APOBEC3G variant.J Virol. 2007 Aug;81(15):8236-46. doi: 10.1128/JVI.02694-06. Epub 2007 May 23. J Virol. 2007. PMID: 17522211 Free PMC article.
-
Multiple Inhibitory Factors Act in the Late Phase of HIV-1 Replication: a Systematic Review of the Literature.Microbiol Mol Biol Rev. 2018 Jan 10;82(1):e00051-17. doi: 10.1128/MMBR.00051-17. Print 2018 Mar. Microbiol Mol Biol Rev. 2018. PMID: 29321222 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases